Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
about
Microvascular vasodilator properties of the angiotensin II type 2 receptor in a mouse model of type 1 diabetes.Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells.Enalapril improves endothelial function in patients with migraine: A randomized, double-blind, placebo-controlled trial.Impact of probiotics on risk factors for cardiovascular diseases. A review.Regulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted miceThe renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndromeEarly treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice.Vascular complications of diabetes: mechanisms of injury and protective factorsAngiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.Activation of retinoid receptor-mediated signaling ameliorates diabetes-induced cardiac dysfunction in Zucker diabetic rats.Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.Why is blood pressure so hard to control in patients with type 2 diabetes?Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity.The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements.The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.Biological pathways and potential targets for prevention and therapy of chronic allograft nephropathyRenal allograft fibrosis: biology and therapeutic targets.Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters.Perindopril protects against streptozotocin-induced hyperglycemic myocardial damage/alterations.Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.High salt intake elevated blood pressure but not changed circadian blood pressure rhythm in Otsuka Long-Evans Tokushima Fatty (OLETF) rat.Health behavior of hypertensive elderly patients and influencing factors.Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties.Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat.Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications.Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats.
P2860
Q30843430-FFC2FEAE-BD59-4887-AC51-464B601D769DQ34060789-D9131528-B9D2-4D94-B00A-08197CB33E15Q34714052-302AF611-BCDC-4F22-B28E-AFED9A78A41BQ35031383-1533900A-5005-4774-B4F8-54456A6E2263Q35050007-3E960E93-F04C-4F6A-BBEC-7CC1E31702C6Q35850133-F4620D19-4C06-4E61-A550-0A20598927BBQ35894709-8685F9DA-08A2-4C05-B42A-2B8FB60595C7Q36036207-EBBD72F2-FF10-434F-A38B-5D61461130CAQ36537262-A8B62433-4563-4C15-8834-0CE3D82FF0FCQ36579769-EB60D292-F6D2-46C3-9E6D-00413717C145Q36673848-995A4570-5B2C-40D7-8C77-1D9393E9B9CFQ36675396-260EB028-3108-4DFA-B9FF-8CFF434FCE6FQ36904456-6B2161FD-C8F6-46D9-84CC-3801EA7E440CQ36936570-9745F915-F534-404F-9581-4BC133CC5937Q36956471-0F14D4E1-EFF5-4A7C-A070-03A9ECA912C0Q37169716-A3B919C8-1C96-457D-B4AE-999310126751Q37326570-F783DEE7-6727-4138-A8C0-833A35666A97Q37611981-BD70CB4C-C8AA-4594-852E-7E02B861035EQ37638064-17EB32E8-32B2-48E0-97EE-B44F87A7DC69Q38223778-8976C6D0-83F2-4DF9-9D8B-4CEE14FD8DC9Q38359455-9291ED07-17B4-44A1-BC29-34AF9B8D4AA7Q41922933-4FD381DB-0AC7-4659-820C-1EC97C559092Q42873491-4858FE03-47F9-4BD9-A9D0-533AD00AC296Q44058520-55F78620-38EE-423D-9D86-991EAA1986C1Q45072634-F80890EB-A6D1-4D3A-A505-54339EE89FB4Q46039856-0C21645C-20EC-47BE-B345-F37F3DFB31EBQ46268507-745A6A2A-1E84-4D47-868C-FCA1F94E19DEQ47296173-1EC93399-63E7-45B4-82AA-4295E99747CBQ47891550-1B1F55E9-2749-48BD-9276-0348A9105AE8Q51743274-5FF12EAC-969E-4D58-A486-D1DB2BE1BD9BQ51785382-AA2735D0-6245-4472-B274-31870AF55EA9
P2860
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Blockade of the renin-angioten ...... nts in patients with diabetes.
@ast
Blockade of the renin-angioten ...... nts in patients with diabetes.
@en
type
label
Blockade of the renin-angioten ...... nts in patients with diabetes.
@ast
Blockade of the renin-angioten ...... nts in patients with diabetes.
@en
prefLabel
Blockade of the renin-angioten ...... nts in patients with diabetes.
@ast
Blockade of the renin-angioten ...... nts in patients with diabetes.
@en
P1476
Blockade of the renin-angioten ...... nts in patients with diabetes.
@en
P2093
Anne Zanchi
Michel Burnier
P356
10.1097/01.HJH.0000191244.91314.9D
P577
2006-01-01T00:00:00Z